D-dimer Products

Article from HyTest’s scientists

Kogan, AE et al. (2016) Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products. Blood Coagul. Fibrinolysis, 2015 Dec 11. [Epub ahead of print] PubMed PMID: 26656897.

The discrepancy between the results obtained by D-dimer assays from different manufacturers is a significant challenge to clinicians in D-dimer determination. The problem is well known but has turned out to be difficult to solve. In this article, we present a new concept for developing a D-dimer immunoassay that could decrease the problems associated with the current assays.

D-dimer and high molecular weight fibrin degradation products

Elevated levels of D-dimer are found in the blood of patients with pulmonary embolism, deep vein thrombosis and atherosclerosis. D-dimer diagnostic tests are widely used to exclude the diagnosis of deep vein thrombosis. In addition, increased amount of D-dimer in blood is believed to be a reliable marker of pathological coagulation that underlies the pathogenesis of most cardiovascular diseases.

D-dimer is the smallest degradation product resulting from fibrinolysis. In fibrinolysis, fibrin clots are digested by plasmin, and fibrin degradation products (FDP) of various sizes are released into the bloodstream. 

For an accurate determination of D-dimer and the varying range of high molecular weight FDPs, the assay should detect FDPs and D-dimer with equal specificity.

We provide several monoclonal antibodies specific to D-dimer and FDP for development of reliable, quantitative D-dimer assays. In addition to antibodies, we offer D-dimer that is produced from clotted fibrinogen by means of plasmin digestion.

Antibodies

Our D-dimer antibody range is suitable for development of sensitive D-dimer assays for different test platforms.

Cat.# Product name
4D30 Monoclonal mouse anti-D-dimer

Antigen

Cat.# Product name
8D70 D-dimer Antigen

TechNotes

D-dimer and High Molecular Weight Fibrin Degradation Products TechNotes

Articles

Kogan AE, et al. (2015) Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products. Blood Coagul. Fibrinolysis, 2015 Dec 11. [Epub ahead of print] PubMed PMID: 26656897.

New D-dimer mAbs (DD189 and DD255) allow developing an improved immunoassay to detect D-dimer

We offer two new monoclonal antibodies which can be used to develop a one-step immunoassay that is equally specific for fibrin degradation products (FDP) and D-dimer.

Why to develop an assay with equal specificity to FDP and D-dimer?

Patient plasma contains a wide variety of FDP of different sizes along with D-dimer itself. All of these products possess the “D-dimer antigen epitope”. Therefore, antibodies specific to D-dimer also recognize FDP. However, there is a great variance between the results obtained by different assays. This can be explained by differences in antibody specificities; some antibodies and antibody pairs recognize D-dimer better than FDP and vice versa. So far all standardization and harmonization attempts have not resulted in satisfying results and this is a continuous cause of problems in daily practice.

The ratio of FDP and D-dimer in blood is not constant but varies from patient to patient. We believe that an assay which equally detects all fibrin degradation products including D-dimer will decrease bias in quantitative detection of all these different degradation products.